PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2026Cells1 citationsOpen Access

Signaling Networks Regulating Metastatic Progression in Triple-Negative Breast Cancer

View Full Paper
ZSZuzanna SenkowskaKOKatarzyna OwczarekKNKarolina Niewinna

Key Points

  • The aim is to summarize the molecular mechanisms involved in metastatic progression in triple-negative breast cancer (TNBC).
  • Review of existing literature on metastatic progression in TNBC
  • Analysis of signaling pathways involved such as PI3K/Akt, TGF-β, and Wnt/β-catenin
  • Discussion on their roles in tumor invasion and the tumor microenvironment
  • Identifies key pathways that regulate metastasis in TNBC
  • Highlights the importance of tumor–microenvironment interactions
  • Suggests potential therapeutic targets for limiting metastatic disease

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive and clinically challenging subtypes of breast cancer, defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. The lack of actionable molecular targets contributes to limited therapeutic options, frequent recurrence, and a high propensity for distant metastasis. Metastatic dissemination remains the principal cause of mortality in patients with TNBC and is driven by complex molecular mechanisms involving multiple interconnected signaling networks. This review summarizes current knowledge of the molecular mechanisms underlying metastatic progression in TNBC, with particular emphasis on signaling pathways that regulate tumor invasion, migration, and colonization of distant organs. We discuss the roles of key pathways, including PI3K/Akt, TGF-β, Wnt/β-catenin, NF-κB, and Rho/ROCK signaling, in the regulation of epithelial–mesenchymal transition, cytoskeletal remodeling, cancer stem cell phenotypes, and tumor–microenvironment interactions. A deeper understanding of these signaling networks may facilitate the identification of novel therapeutic targets and support the development of more effective strategies to limit metastatic disease in TNBC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Senkowska et al. (2026) studied this question.

synapsesocial.com/papers/69fa8eca04f884e66b5311b6https://doi.org/10.3390/cells15090809
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies2025 · 5 citations
  2. 2Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies2025
  3. 3Next-Generation Therapeutic Targets in Triple-Negative Breast Cancer2026
  4. 4Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  5. 5Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using single-cell RNA sequencing analysis2024 · 11 citations